RxDoctor Payments Data

Wyzscx Patacxil, MD

Surgery · El Segundo, CANPI 1932543675

Payments from drug & device makers

$6,038in general payments, 2019–2025

Across 80 payments — averaging $75.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Smith+Nephew$4K
  • Mimedx Group, Inc.$1K
  • Kerecis Limited$317
  • Triad Life Sciences Inc.$233
  • Next Science LLC$172
  • Inari Medical, Inc.$158
  • plus $302 from 3 others

What the payments were for

  • Travel & lodging$1,89231%
  • Food & beverage$3,80963%
  • Education$3376%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,038 in reported general payments places this provider in the 65th percentile of 2,363 surgery providers in California.

See all surgery providers in California

Medicare billing

Part B allowed, 2024
$4,790,482
Medicare patients
216
Services billed
5,876

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SantylCollagenase Clostridium Hist.49$286,636
EliquisApixaban181$84,974
JardianceEmpagliflozin52$33,957
OzempicSemaglutide25$25,892
XareltoRivaroxaban33$17,542
JanuviaSitagliptin Phosphate26$16,251
FarxigaDapagliflozin Propanediol21$12,421
Atrovent HfaIpratropium Bromide19$9,954
EntrestoSacubitril/Valsartan15$9,341
Tresiba Flextouch U-100Insulin Degludec16$7,460
VascepaIcosapent Ethyl32$5,652
CreonLipase/Protease/Amylase14$4,863
RhopressaNetarsudil Mesylate13$4,409
Oxycodone Hcl113$4,402
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen115$3,493

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Smith+NephewSantyl$3,510$286,63649 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,363 surgery providers in California.

Other surgery in El Segundo

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →